T Cell Defects: New Insights Into the Primary Resistance Factor to CD19/CD22 Cocktail CAR T-Cell Immunotherapy in Diffuse Large B-Cell Lymphoma

Despite impressive progress, a significant portion of patients still experience primary or secondary resistance to chimeric antigen receptor (CAR) T-cell immunotherapy for relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL). The mechanism of primary resistance involves T-cell extrinsic and...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jiachen, Shen, Kefeng, Mu, Wei, Li, Weigang, Zhang, Meilan, Zhang, Wei, Li, Zhe, Ge, Tong, Zhu, Zhoujie, Zhang, Shangkun, Chen, Caixia, Xing, Shugang, Zhu, Li, Chen, Liting, Wang, Na, Huang, Liang, Li, Dengju, Xiao, Min, Zhou, Jianfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9094425/
https://www.ncbi.nlm.nih.gov/pubmed/35572515
http://dx.doi.org/10.3389/fimmu.2022.873789

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9094425/
https://www.ncbi.nlm.nih.gov/pubmed/35572515
http://dx.doi.org/10.3389/fimmu.2022.873789

Ejemplares similares